Researchers have proposed three pathways, studied mainly in human taste tests, cell models and animals. These are proposed mechanisms, not confirmed clinical effects. Gymnemic acids on the tongue can temporarily blunt the perception of sweetness for roughly 30 to 60 minutes. Because these acids resemble glucose, they may compete with it at intestinal absorption sites and slow how fast sugar enters the bloodstream, an effect seen mainly in the laboratory and in animals. Leaf glycosides have also been reported to increase glucose uptake in cell models.

Published research points to three proposed pathways, studied mainly in cell and animal models. Cucurbitane-type glycosides have been reported to stimulate glucose uptake by activating the AMPK pathway, which helps move the GLUT4 glucose transporter. An insulin-like protein (polypeptide-p) lowered glucose in animal models when injected, although its contribution from the fruit eaten as food is uncertain. A saponin fraction inhibits intestinal disaccharidases and pancreatic lipase, slowing how fast glucose and fat enter the bloodstream after meals. These are laboratory and animal findings, not confirmed clinical effects.

Published research points to three proposed pathways, studied mainly in the laboratory and in animals. The amino acid 4-hydroxyisoleucine has been reported to support glucose-dependent insulin secretion in isolated pancreatic tissue, a laboratory finding rather than a clinical outcome. The seed's soluble galactomannan fibre has been studied in relation to slower post-meal glucose absorption. Seed extract has shown glucose-lowering activity attributed to insulin signalling in an animal model. A 2014 meta-analysis pooled controlled trials on glycaemic markers, though the underlying trials were generally small.

The mechanisms below are reported in animal and laboratory research only, and have not been confirmed in human trials. A flavonoid-rich seed extract lowered glucose and blood lipids in diabetic rats. A fruit-pulp fraction acted through both pancreatic and extra-pancreatic routes in diabetic animals, suggesting more than one route of action in the model. Reviews also catalogue an interaction with alpha-glucosidase and starch breakdown, framed as preclinical and traditional rather than clinically established.

The published research is mostly preclinical and traditional. In a comparative animal study, neem leaf extract showed glucose-lowering activity attributed to greater peripheral glucose use; this is from an animal model and has not been confirmed in humans. Reviews of Indian medicinal plants list neem among species with reported hypoglycaemic constituents, but the underlying data are largely preclinical or traditional. Neem leaf constituents have also shown antioxidant and anti-inflammatory activity in laboratory and rodent models. Two of the references below address neem's safety profile rather than glucose, covering kidney and reproductive safety in animal models; they are included because a herb's safety is part of any responsible evaluation.

The proposed mechanisms below are preclinical only, observed in isolated-compound or animal studies. They have not been confirmed in humans. Isolated swertiamarin modulated liver and fat-tissue gene expression linked to PPAR-gamma in diabetic rats. An aqueous whole-plant extract was linked to changes in fasting glucose, insulin sensitivity and lipid levels in chemically-induced diabetic rats. Swertiamarin also showed antioxidant and liver-protective effects in a rat model.